Glicosamina e Diabetes / Glicosamine and Diabetes

É comum pessoas com algum tipo de desgaste articular usar dessa suplementação para o combate e/ou prevenção da progressão. Mas a algum tempo publicações tem demonstrado que a glicosamina pode desempenhar um efeito colateral relevante, causando a resistência à ação da insulina. 

It's usual that people with osteoarthritis disease used these supplementation to tackle and/or prevent the development of the disease. Over the past few years the lecture has demonstrated that the glicosamine could play a adverse effect. This supplementation could cause insulin resistance and a recent study shows these strategies do not prevent development of osteoarthritis.

http://www.healthgalleries.com/arthritis-osteoarthritis

References:

1: Muniyappa R. Glucosamine and osteoarthritis: time to quit? Diabetes Metab Res Rev. 2011

 Mar;27(3):233-4. doi: 10.1002/dmrr.1179. PubMed PMID: 21370382.

2: Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP. The effect of glucosamine 

on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartil 

ge. 2011 Apr;19(4):375-80. doi: 10.1016/j.joca.2011.01.007. Epub 2011 Jan 18. Review. 

PubMed PMID: 21251987.

3: Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses used to 

treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007 Jun;333(6):333-9. 

PubMed PMID: 17570985.

http://www.healthgalleries.com/arthritis-osteoarthritis

Ranelato de Estrôncio

Esse novo principio ativo tem recentemente surgido nas pesquisas cientificas mostrando se muito eficiente no tratamento de osteoporose em mulheres no período pós-menopausa, diminuindo o risco de fraturas ósseas, agindo sobre os fatores de formação e reabsorção óssea. Esses fatores apontados levaram a utilização desse fármaco no tratamento de artrose. Os estudos até o momento mostraram segurança nesse tratamento.

Endokrynol Pol. 2011;62 Suppl 2:23-31.

[Strontium ranelate in post-menopausal osteoporosis].

[Article in Polish]

Przedlacki J.

Source

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, Warszawa. jprzedlacki@amwaw.edu.pl

Abstract

Strontium ranelate is one of the first-line agents with proven anti-fracture activity used in the therapy of post-menopausal osteoporosis. Its mechanism of action makes it, however, different from other drugs, since it simultaneously stimulates two reverse processes: bone formation and bone resorption. The action of the agent depends on various mechanisms, including the activation of calcium receptors, localised on osteoblasts and osteoclasts, and on the influence on the OPG/RANKL system. The drug effectively prevents spinal, hip and extravertebral fractures. The agent's anti-fracture efficacy within the spine does not depend on the patient's age, or on base BMD values, or on the concentration of bone metabolism markers. As to the anti-fracture efficacy in the hip, it concerns women with an increased bone fracture risk. Strontium ranelate increases bone mineral density within the lumbar spine and the hip, decreases the concentrations of bone resorption markers, and increases the concentrations of bone formation markers. The drug is administered in a daily 2.0 g oral dose. This paper presents indications to therapy with strontium ranelate, specifying also its side effects and contraindications. We compare the anti-fracture efficacy of strontium ranelate to the efficacy of other agents of proven anti-fracture activity, based on published clinical studies.